Drug Discovery

Gilead Sciences acquires Tubulis for $5bn

Gilead Sciences has concluded its acquisition of Tubulis, a Germany-based biotechnology company developing next-generation antibody-drug conjugates (ADCs), in a transaction valued at up to $5bn.

FUJIFILM opens new iPSC facility in Madison, US

FUJIFILM Cellular Dynamics has opened a new headquarters and induced pluripotent stem cell (iPSC) manufacturing facility in Madison, Wisconsin, US.

BMS and Anthropic collaborate for Claude implementation

Bristol Myers Squibb (BMS) has signed a strategic agreement with Anthropic to implement its Claude platform across its global operations.

QIAGEN and NVIDIA partner on AI drug discovery

QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery.

VERTANICAL’s VER-01 gains FDA breakthrough status for low back pain

VERTANICAL has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for VER-01, its investigational non-opioid treatment for chronic low back pain.

Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates

Regeneron Pharmaceuticals has signed a $2.32bn research collaboration with Parabilis Medicines to develop therapeutic candidates leveraging the latter’s Helicon peptide platform, with an emphasis on antibody-Helicon conjugates (AHCs).

Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF

Boehringer Ingelheim has received Japan’s Ministry of Health, Labour and Welfare (MHLW) approval for Jascayd (nerandomilast) to treat adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

Arna Pharma and Slate Run complete JV for new US company

Arna Pharma and Slate Run Pharmaceuticals have completed a joint venture (JV) to form a speciality pharmaceutical company in the US focusing on branded products, 505(b)(2) medicines, and specialised generics.

Kyowa Kirin secures FDA approval for Crysvita dosing update

Kyowa Kirin has received approval from the US Food and Drug Administration (FDA) for a dosing update to the prescribing information for Crysvita (burosumab-twza), introducing a new option for adults with X-linked hypophosphataemia (XLH).